EA201690861A1 - Нуклеиновокислотные модуляторы белка alpha2beta1 - Google Patents

Нуклеиновокислотные модуляторы белка alpha2beta1

Info

Publication number
EA201690861A1
EA201690861A1 EA201690861A EA201690861A EA201690861A1 EA 201690861 A1 EA201690861 A1 EA 201690861A1 EA 201690861 A EA201690861 A EA 201690861A EA 201690861 A EA201690861 A EA 201690861A EA 201690861 A1 EA201690861 A1 EA 201690861A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nucleic acid
protein
nuclein
acid ligand
modulator
Prior art date
Application number
EA201690861A
Other languages
English (en)
Inventor
Кристофер Рускони
Джулиана Лейзер
Original Assignee
ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" filed Critical ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика"
Publication of EA201690861A1 publication Critical patent/EA201690861A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предлагаются композиции, включающие нуклеиновокислотый лиганд и/или модулятор, а также способы применения этих агентов и композиций в лечении α2β1-опосредованных заболеваний и нарушений. Также предлагается фармакологическая система, содержащая нуклеиновокислотный лиганд, который связывается с белком интегрином α2β1 и регулирует его активность. Кроме того, эти нуклеиновокислотные лиганды активно обратимы при использовании модулятора, который ингибирует активность нуклеиновокислотного лиганда с нейтрализацией его фармакологического эффекта, тем самым восстанавливает функцию α2β1.
EA201690861A 2012-10-24 2013-10-14 Нуклеиновокислотные модуляторы белка alpha2beta1 EA201690861A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261717944P 2012-10-24 2012-10-24
PCT/US2013/064829 WO2014066084A1 (en) 2012-10-24 2013-10-14 Nucleic acid modulators of alpha2beta1

Publications (1)

Publication Number Publication Date
EA201690861A1 true EA201690861A1 (ru) 2016-08-31

Family

ID=50545113

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690861A EA201690861A1 (ru) 2012-10-24 2013-10-14 Нуклеиновокислотные модуляторы белка alpha2beta1

Country Status (2)

Country Link
EA (1) EA201690861A1 (ru)
WO (1) WO2014066084A1 (ru)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4721901A (en) * 2000-02-25 2001-09-03 Immunex Corp Integrin antagonists
AU2775402A (en) * 2001-06-29 2003-01-02 Medimolecular Pty Ltd Nucleic acid ligands to complex targets
KR101185050B1 (ko) * 2004-04-22 2012-10-04 레가도 바이오사이언스, 인코포레이티드 응고 인자의 개선된 모듈레이터

Also Published As

Publication number Publication date
WO2014066084A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
EA201790134A3 (ru) Соединения имидазопирролидинонов
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201400993A1 (ru) Антитела против рецептора эпидермального фактора роста, активные в определенных условиях, и способы их применения
EA201690567A1 (ru) Антитела против pd1 и их применение в качестве терапевтических и диагностических средств
EA201492219A1 (ru) Соединения и композиции для модуляции egfr активности
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201491541A1 (ru) АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
EA201491656A1 (ru) Связывающие молекулы человека, способные связываться с вирусами гриппа в и нейтрализовать их, и их применения
UY34995A (es) Formulaciones de anticuerpo y proteína
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
WO2014031646A3 (en) Molecules with antigen binding and polyvalent fc gamma receptor binding activity
EA201591762A1 (ru) Человеческие антитела к grem1
EA201491530A1 (ru) Модуляторы рецепторов эстрогенов и их применение
EA201391416A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201591618A1 (ru) Замещенные имидазопиридазины
EA201990403A1 (ru) Человеческие анти-vegfr-2/kdr-антитела
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
UY34553A (es) Procedimiento de preparación de la sal de l-arginina de perindoprilo